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Abstract
Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that
occur when non-radioactive 10B is irradiated with low energy thermal neutrons to produce αparticles (10B[n,α]7Li). Carboranylporphyrins are a class of substituted porphyrins containing
multiple carborane clusters. Three of these have been evaluated in the present study: 5,10,15,20tetra-(4-nido-carboranyphenyl)tetrabenzoporphyrin (H2TBP), 5,10,15,20-tetra-(4-nidocarboranylphenyl)porphyrin (H2TCP) and 5,15-di-[3,5-(nido-carboranylmethyl)phenyl]-porphyrin
(H2DCP). The goals of this study were two-fold. First, to determine the biodistribution of H2TBP,
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H2TCP and H2DCP following intracerebral (i.c.) administration by means of short term (30 min)
convection enhanced delivery (CED) or sustained delivery over 24 h by osmotic pumps to F98
glioma bearing rats. Second, to determine the efficacy of H2TCP and H2TBP as boron delivery
agents for BNCT in F98 glioma bearing rats. Tumor boron concentrations immediately after i.c.
osmotic pump delivery were high (36–88 µg/g) and they remained so at 24 h (62–103 µg/g) The
corresponding normal brain concentrations were low (0.8–5.2 µg/g) and the blood and liver
concentrations were all undetectable. Based on these data, therapy studies were initiated at the
Massachusetts Institute of Technology (MIT) Research Reactor (MITRR) with H2TCP and
H2TBP 24 h after CED or osmotic pump delivery. Mean survival times (MST) of untreated and
irradiated control rats were 23±3 and 27±3 d, respectively, while animals that received H2TCP or
H2TBP, followed by BNCT, had a MST of 35±4 d and 44±10 d, respectively, which were better
than those obtained following i.v. administration of boronophenylalanine (37±3 d). However,
since the tumor boron concentrations of the carboranylporphyrins were 3–5X > i.v. BPA (~25 µg/
g), we had expected that the MSTs would have been greater. Histopathologic examination of
brains of BNCT treated rats revealed that there were large numbers of porphyrin-laden
macrophages, as well as extracellular accumulations of porphyrins indicating that the seemingly
high tumor boron concentrations did not represent the true tumor cellular uptake. Our data are the
first to show that carboranyl porphyrins are effective delivery agents for BNCT of an experimental
brain tumor. Based on these results, we now are in the process of evaluating carboranylporphyrins
that could have enhanced cellular uptake following administration and improved therapeutic
efficacy.

Keywords
convection enhanced delivery; carboranylporphyrins; boron neutron capture therapy; F98 rat
glioma

Introduction
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Boron neutron capture therapy is based on the nuclear capture and fission reactions that
occur when non-radioactive boron-10 is irradiated with neutrons of the appropriate energy to
yield high energy alpha particles (4He) and recoiling lithium-7 (7Li) nuclei. Since these
particles have pathlengths of approximately one cell diameter, their lethality primarily is
limited to boron containing cells. BNCT, therefore, can be regarded as both a biologically
and a physically targeted type of radiation therapy. Its success is dependent upon the
selective delivery of sufficient amounts of 10B to cancer cells with only small amounts
localized in the surrounding normal tissues. A wide variety of boron delivery agents have
been synthesized [1], but only two of these currently are being used in clinical trials. The
first, which has been used primarily in Japan, is sodium borocaptate or BSH, and the second
is a dihydroxyboryl derivative of phenylalanine referred to as boronophenylalanine or BPA.
The latter has been used in clinical trials in the United States, Europe, and more recently in
Japan [2]. Following administration of either BPA or BSH by intravenous (i.v.) infusion, the
tumor site is irradiated with neutrons, the source of which is a nuclear reactor. Interested
readers are referred to the recently published proceedings of the Thirteenth International
Congress on Neutron Capture Therapy for more detailed information relating to BNCT [3].
There has been a long-standing interest on the part of a number of research groups on the
design, synthesis and biological evaluation of boron-containing porphyrins as delivery
agents for BNCT [4–15]. For more information on this subject, interested readers are
referred to comprehensive reviews on boronated porphyrins [16,17]. The
carboranylporphyrins used in the present study belong to a class of meso-substituted
porphyrins containing four nido-carborane clusters and 36 boron atoms per molecule
J Neurooncol. Author manuscript; available in PMC 2011 June 1.
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(37-31% boron by weight), linked to the porphyrin macrocycle via hydrolytically-stable
carbon-carbon bonds. These compounds have been designated 5,10,15,20-tetra-(4-nidocarbo-ranylphenyl)tetrabenzoporphyrin (H2TBP), 5,10,15,20-tetra-(4-nidocarboranylphenyl)porphyrin (H2TCP) and 5,15-di-[3,5-(nido-methyl)phenyl]porphyrin
(H2DCP) and their structures are shown in Fig. 1. The synthesis and preliminary biological
investigations of H2TCP [18–21], H2DCP [21,22] and H2TBP [23,24] previously have been
reported. Earlier studies [18–20,22–24] suggested that H2TCP, H2DCP and H2TBP were
promising boron delivery agents due to their low toxicity and tumor targeting properties.
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Based on the reports of Ozawa et al. [25,26] and our own experience with CED [27], we
decided to focus on direct intracerebral (i.c.) delivery of the carboranylporphyrins rather
than systemic administration. CED is an innovative method for local drug delivery to brain
tumors by which a pressure gradient, or bulk flow, is used to drive an infusate through the
extracellular fluid compartment [28]. It allows delivery of the infusate to the tumor and
surrounding brain at much higher concentrations than could be achieve by systemic
administration. As demonstrated in both animal studies [27,29] and clinical trials [30,31],
CED not only increased the delivery of both low and high molecular weight agents, but also
improved their therapeutic efficacy. Initially, we carried out some preliminary studies with
several carboranylporphyrins using the F98 rat glioma model [32–34] and we now present a
more detailed evaluation of the biodistribution and efficacy of H2TCP, H2DCP and H2TBP
as potential boron delivery agents for neutron capture therapy (NCT).

Material and Methods
Synthesis of carboranylporphyrins
All nido-carboranylporphyrins were synthesized via the base for H2TCP and H2DCP, or the
fluoride ion for H2TBP induced degradation of the corresponding closocarboranylporphyrins [35]. Therefore, all of them were mixture of stereoisomers, as shown
by 1H-NMR spectra and ab initio calculations, and this might contribute to their therapeutic
efficacy. The percent boron by weight of these was 27% for H2TBP and 31% for H2TCP
and H2DCP. Two of these were converted to their zinc complexes, ZnDCP and ZnTCP, for
the biodistribution studies described below. These compounds were all stable for months at
physiologic temperatures, but they were light sensitive and, therefore, they were shielded
from light prior to their administration.
Biodistribution of ZnDCP and ZnTCP in glioma bearing mice
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Biodistribution studies were carried out in female C57Bl/6 mice (Animal Production
Branch, National Cancer Institute, Frederick, MD), weighing 20–25 g, bearing the syngenic
murine GL261 glioma. This tumor was induced by the intracerebral (i.c.) implantation of
methylcholanthrene pellets into the brain of a C57Bl/6 mouse [36]. It is composed of poorly
differentiated cells histopathologically consistent with a glioblastoma. Tumor cells were
implanted subcutaneously (s.c.) into the right dorsum with an inoculum of 1.8 × 106 cells.
Biodistribution studies were carried out 15 d after implantation at which time the tumor
volumes were ~ 80 mm3. The zinc(II) complexes of H2DCP and H2TCP, ZnDCP and
ZnTCP, respectively, were injected intraperitoneally (i.p.) over 8 hours in 3 doses totaling
30 mg boron/kg body weight (b.w.). Since these compounds are photosensitizers, the
animals were shielded from light during the course of the experiment. In order to compare
their biodistribution with that of BPA, another group of mice received a single i.p. injection
of BPA at a concentration of 500 mg/kg b.w. Mice were euthanized at 24 and 48 h following
the first injection and tissue and blood samples were taken for boron determinations by
means of direct current plasma-atomic emission spectroscopy (DCP-AES), as previously
described by us [37]. All animal studies were done in accordance with the Guide for the
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Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) and
the protocol was approved by the Institutional Laboratory Care and Use Committee of The
Ohio State University.
F98 rat glioma model
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The F98 rat glioma (#CRL-2397, American Type Culture Collection, Manasus, VA) was
derived from an undifferentiated neoplasm transplacentally induced in the progeny of a
pregnant CD Fischer rat by the i.v. administration of N-ethyl-N-nitrosourea [38]. It has been
propagated in vitro and in vivo since 1971 and, as described in a recent review [39], the F98
glioma has been used in a wide variety of studies in experimental neuro-oncology. This
tumor has an infiltrative pattern of growth within the brain, and an i.c. inoculum of as few as
ten cells can be fatal. In the present study, F98 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) (Hyclone, Logan, UT), 100 units/ml penicillin, 100 µg/mL streptomycin and 2
mM L-glutamine. Fischer rats (Animal Production Branch, National Cancer Institute,
Frederick, MD), weighing 220–240 g, were used in these studies. A stereotactic
implantation procedure, which has been described in detail elsewhere, was employed [40].
Briefly, rats were sedated by i.p. administration of a 1.2:1 mixture of ketamine/xylazine at a
dose of 120 mg of ketamine/20 mg xylazine/kg body weight (b.w.). Following this, a small
burr hole was drilled into the calvarium and a plastic screw with an entry port (Arrow
Machine Manufacturing, Inc., Richmond, VA) was embedded into the skull. F98 cells at a
concentration of either 103 for therapy studies or 105 cells for biodistribution studies were
injected stereotactically into the right caudate nucleus over 10–15 sec through a small entry
port of the plastic screw. Following this, the entry port was filled with bone wax
immediately after withdrawal of the needle, and the operative field was flushed with
betadine before the scalp incision was closed with a single sterilized clip. Eleven to 13 d
after tumor implantation of 105 cells, when clinical signs of a progressively growing i.c.
tumor were evident, biodistribution studies were initiated.
Biodistribution studies in F98 glioma bearing rats following convection-enhanced delivery
(CED) of carboranylporphyrins
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Since the zinc(II) complexes of carboranylporphyrins have lower cellular uptake than the
free base porphyrins, studies then were carried out with H2DCP and H2TCP. In order to
increase tumor uptake and decrease uptake by extracranial organs and tissues, these were
administered i.c. by means of CED or Alzet pump infusion. Eleven to 13 d after tumor
implantation, when signs of a progressively growing i.c. tumor were evident (weight loss,
lethargy, hunching, and ataxia), biodistribution studies were initiated, at which time the
animals had tumors weighing ~90–180 mg. In contrast to the biodistribution studies carried
out in mice that had received the test porphyrins by i.p. injection, it was not necessary to
shield these rats from light. For short term CED of the boronated porphyrins, a plastic
cannula was inserted into the entry port of the plastic screw and then advanced 5 mm below
the dura into the tumor. The boronated porphyrins were diluted with phosphate buffered
saline (PBS), pH 7.4, to yield a concentration of 0.1–0.2 mg B/10µl. As described by us in
detail elsewhere [40], these compounds were administered by CED at rate 3.3 µl/min for 30
min using a syringe pump (Harvard Apparatus Co, Cambridge, MA). Biodistribution was
determined immediately after and 24 and 48 h after termination of CED. Animals were
euthanized by an overdose of halothane following which tumors and normal tissues,
consisting of brain, blood, liver, kidney and muscle, were removed and weighed. Uptake of
boron was quantified by means of DCP-AES [37].
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NIH-PA Author Manuscript

Alzet osmotic pumps (model #2001 D) and brain infusion kits (rigid stainless-steel cannula,
7 mm 28 gauge) were assembled and filled with 200 µl of the test carboranylporphyrins. The
pumps were stored in the dark in a sterile solution of 0.9% saline at 37°C for 24 h prior to
their use. Fourteen days after tumor implantation, the rats were anesthetized again and the
scalp reopened. The pumps were implanted s.c. between the scapulae. The infusion cannula
and needle were inserted stereotactically into the entry port of the plastic screw and the
needle was advanced 5 mm below the dura into the tumor of glioma bearing rats. H2DCP,
H2TCP or H2TBP at varying doses, ranging from 0.2 – 1.0 mg, were delivered in volume of
200 µl at a constant flow rate of 8 µl/h over 24 h following which the animals were
euthanized immediately (t=0) or 24 or 48 h later. Boron concentrations were determined in
samples of tumor, brain, blood, liver, spleen, kidneys, lungs and heart by means of DCPAES.
Therapy experiments
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BNCT was performed 14 d following stereotactic implantation of 103 F98 glioma cells. Rats
were transported to the Nuclear Reactor Laboratory at the Massachusetts Institute of
Technology (MIT). Based on the results of the biodistribution study, a total of either 0.2 mg
of the compound was administered by CED for 30 min or 0.5 mg of the compound was
infused for 24 h by Alzet pumps. The animals were then randomized on the basis of weight
into experimental groups of 9–10 animals each as follows: Group 1, H2TCP, administered
by Alzet pumps and BNCT; Group 2, H2TBP and BNCT; Group 3, H2TBC by CED and
BNCT; Group 4, CED of H2TBP + i.v. BPA and BNCT; Group 5, i.v. BPA, followed 2.5 h
later by BNCT; Group 6, CED of saline and neutron irradiation; Group 7, unirradiated
controls that received H2TCP by CED. BNCT was initiated 24 h after termination of CED or
infusion and 2.5 h after i.v. administration of 10B enriched BPA at a dose of 500 mg/kg b.w.
(Ryscor Science, Inc., Raleigh, NC). All irradiated rats were anesthetized with a mixture of
ketamine and xylazine. BNCT was carried out at the MITR-II reactor in the M011
irradiation facility, which produces a beam of thermal neutrons of high purity and intensity
with no measurable fast neutron component. Two rats at a time were positioned in a 6Li
enriched polyethylene box that provided whole body shielding from the thermal neutrons
during an irradiation. The animals’ heads were aligned in the middle of a 13×2 cm2 aperture,
machined in the box lid, which served as the beam delimiter. Four fission counters, located
at the periphery of the 15 cm circular field automatically controlled beam delivery and
provided real time data on the relative neutron fluence during an irradiation.
Dosimetry
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After completion of BNCT, the animals were held at MIT for ~ 3 d to allow induced
radioactivity to decay before they were returned to The Ohio State University in Columbus,
OH for clinical monitoring. Dosimetric measurements were performed using bare gold foils
and a graphite walled ionization chamber (V = 0.1 cm3) flushed with reagent grade CO2 on
both dead rats and phantoms made from type 6 nylon [41]. The measured dose rates in brain
(2.2% nitrogen by weight), normalized to the reactor operating at a power of 5 MW, were
18.5 cGy/min for photons, 7.7 cGy/min for thermal neutrons from the nitrogen capture
reaction and 3.4 cGy/min per µg 10B in tissues. For dosimetric calculations, boron
concentrations were determined in tumor, normal brain, liver and blood in a separate group
of animals 24 h after CED of carboranylporphyrins and 2.5 h after i.v. injection of BPA.
Animal irradiations were performed with the reactor operating at a power between 4.0 and
4.8 MW, and these took approximately 7 min to deliver a thermal neutron fluence of 2.64 ×
1012 n.cm−2 to complement previous dose prescriptions [42].
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Monitoring of clinical status and neuropathologic evaluation
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All animals were weighed three times per week and their clinical status was evaluated at the
same time. Once the animals had progressively growing tumors, as evidenced by the
combination of sustained weight loss, ataxia and peri-orbital hemorrhage, they were
euthanized in order to minimize discomfort. Survival times were determined by adding one
day to the time between tumor implantation and euthanization. The brains of all animals in
the therapy studies were removed after death, fixed in 10% buffered formalin, and then cut
coronally at the level of the optic chiasm and 2 mm anterior and posterior to it. Tissue
sections through the tumor were embedded in paraffin, cut at 4 µm, stained with
hematoxylin and eosin (H&E), and examined microscopically to assess the histopathologic
changes.
Statistical evaluation
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The means and standard deviations (SD) were computed for boron concentrations in all the
major organs of C57B1/6 mice bearing s.c implants of the GL261 murine glioma described
in Table 1, and for the tumor, brain, and blood of the F98 glioma rats described in Table 2.
Tumor: brain and tumor:blood boron concentration ratios were calculated for each group. To
study the effects of BNCT on survival of F98 glioma bearing rats, the mean survival time
(MST), standard error (SE), and median survival time (MeST) were calculated for each
group using the Kaplan-Meier estimate [43]. Kaplan-Meier curves also were plotted for all
groups. An overall log rank test was performed to test for equality of survival curves over
the groups. Wald tests were used for individual comparisons between two groups, with a
Bonferroni method of adjustment for multiple comparisons [44]. Since there was no
censoring of the survival data, a two sample t test also was used to compare MSTs in order
to increase the power of the test. The percent increased life span (% ILS) was determined
from the following equation:

where “t” designates treated and “u” designates untreated animals

Results
Biodistribution after systemic injection of carboranylporphyrins
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Following i.p. injection of either ZnDCP or ZnTCP (30 mg/kg b.w.) to GL261 tumor
bearing mice, one of five animals in each group died within the first 24 h and the others
demonstrated reduced activity, suggesting that these doses of the zinc complexes were toxic.
In contrast, H2DCP and H2TCP previously were shown to have very low toxicity [22,23].
The boron uptake in tumor and normal tissues at 24 and 48 h following the third i.p.
injection are summarized in Table 1. The tumor boron concentrations at 48 h were 7.6±1.9
and 5.2±0.3 µg/g of tissue for ZnDCP and ZnTCP, respectively, compared to 1.2±0.4 and
0.5±.1 µg/g in normal brain. In contrast, the 48 h boron concentrations for ZnDPT and
ZnTCP in the liver were 154.9±28.4 and 46.3±11.5 µg/g, respectively, and the spleen
concentrations were 138.5±60.1 and 114.0±99.1 µg/g with marked animal to animal
variability. This possibly reflected differences in the excretion of the compounds and their
metabolites. The corresponding blood concentrations were 15.9±3.5 and 11.3±2.5 µg/ml,
respectively. Based on these data, a decision was made to administer the
carboranylporphyrins i.c. either by short term (30 min) CED or by a 24 h infusion using
Alzet pumps. In contrast to the high extracranial tissue uptake of ZnDCP and ZnTCP, BPA
had very low concentrations in all organs except for tumor (12.5±4.1 µg/g).
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Biodistribution following delivery of carboranylporphyrins by either CED or Alzet pumps
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As shown in Tables 2 and 3, administration by either Alzet pumps or CED resulted in higher
tumor and lower normal tissue boron concentrations, and improved tumor:brain (T:Br) and
tumor: blood (T:Bl) ratios compared to those obtained following i.p. injection (Table 1). The
boron concentrations in tumor and selected normal tissues in F98 glioma bearing rats
following Alzet pump delivery of H2TCP at doses of 0.2, 0.5 or 1.0 mg/200 µl, delivered i.c.
into F98 glioma bearing rats are summarized in Table 2. Tumor boron concentrations were
clearly dose dependent immediately following infusion and at 24 and 48 h later. The highest
tumor boron concentrations were observed at 24 h following administration of escalating
doses of H2TCP (24.6, 102.9 and 149.6 µg/g), but these were all within 1 SD of the
concentrations that were observed immediately following infusion, indicating that there was
retention and possibly some accretion of boron within the tumor. In contrast, the tumor
concentrations had fallen quite precipitously by 48 h to values that were one-third of their
peak value, while the normal brain and blood values were low at the three time points (0.2 to
3.3 µg/g) except for those animals that received the 1.0 mg dose. Their normal brain values
were higher at 0, 25 and 48 h (6.5, 10.1 and 3.0 µg/g, respectively). Although the highest
T:Br ratio was seen with the dose of 0.5 mg at 48 h after administration, the tumor boron
concentration was low (16.8 µg/g). Therefore, the most favorable values of tumor boron
(102.9 µg/g) and T:Br ratios for H2TCP were seen with this dose at 24 h. In contrast, the
tumor boron values for H2TBP and H2DCP at the same time and dose were 61.9±16.4 and
35.6±9.0 µg/g, respectively (Table 3). The highest tumor boron concentration was seen 24 h
following short term (30 min) CED of H2TBP (140.3±70.9 µg), but as indicated by the large
SD, there was considerable animal to animal variability. It should be noted that the T:Br
boron concentration ratios of the carboranylporphyrins were markedly increased over those
that we have observed following either intravenous (i.v) or intracarotid (i.c.) administration
of BPA and BSH [40].
Boron neutron capture therapy
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The carboranylporphyrins were administered 14 days following tumor implantation and
BNCT was carried out 24 h after termination of delivery. This was well tolerated and weight
loss in the first week was less than 20%, following which the animals regained their weight.
The estimated physical radiation doses delivered to tumor, brain and blood were calculated
according to boron concentrations summarized in Table 3. In contrast, following i.c.
administration of the carboranylporphyrins no boron was detected in samples of liver,
spleen, kidneys, lungs and heart (data not shown). The highest physical radiation doses
delivered to the tumor were 39.1 Gy for H2TBP by CED and 29.2 Gy for H2TCP by Alzet
pump infusion. The corresponding normal brain doses were 2.3 and 2.9 Gy (Table 3). The
survival data following BNCT are summarized in Table 4, and Kaplan Meier survival plots
are shown in Fig 2, 3 and 4. The MSTs were 35.0±3.7 d and 43.8±10 d, respectively, for rats
that received H2TCP and H2TBP by Alzet pump (Table 4). Animals that received H2TBP
had significantly longer survival times than those that received H2DCP (p<0.017). Further
studies were carried out using H2TBP at a dose of 0.2 mg, administered by CED, either
alone or in combination with i.v. BPA. The corresponding MSTs were 33.8±3.1 d and
42.8±9.0 d, respectively (Table 4 and Fig. 3). As shown in Fig. 4, there were more long term
survivors among rats that received the combination of i.v. BPA and H2TBP, compared those
that received H2TBP alone (p<0.001). The animals that received of H2TBP by Alzet pump
(Table 4 and Fig. 5) had longer MSTs than those that received it by CED (43.8 versus 33.8
d), demonstrating that Alzet pump delivery was more effective than CED (p<0.013).
However, it must be recognized that statistical significance is not necessarily the same as
biological (or clinical) significance. If the MSTs of animals that received i.v. BPA are
compared to those that received H2TBP using a two sample t test, then they were not
significantly different from one another (p=0.38). The highest %ILS (87.2%) was observed
J Neurooncol. Author manuscript; available in PMC 2011 June 1.
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among those animals that received H2TBP by osmotic pumps and this was equivalent to the
%ILS of animals that received the combination of H2TBP by CED and i.v. BPA (82.8%).
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Neuropathologic evaluation
The most notable histopathologic finding was the presence of porphyrin laden macrophages
and extracellular deposits of porphyrins in the tumors of many of the rats that received either
H2TCP or H2TBP by either CED or Alzet pump infusion (Fig. 5A and B). As shown in Fig.
5B, this material was bright orange in color and was easily discernible on H&E stained
sections of the tumor. In most instances, the appearance of the tumor in both treated and
untreated animals was similar to that previously described by us [39]. Briefly, the tumor was
composed of cells that varied in size and shape from ovoid to fusiform, sometimes
displaying a whorled pattern of growth. Frequently, there were microscopic deposits of
tumor cells invading the surrounding white matter and a central zone of necrosis. There were
focal infiltrates of polymorphonuclear leukocytes in the tumors of several untreated and
irradiate control animals, suggesting that there had been bacterial contamination at the time
of their implantation. In these cases, the tumors were much smaller than those usually seen.

Discussion
NIH-PA Author Manuscript

Biodistribution studies demonstrated that high tumor boron concentrations could be
achieved by either short term (30 min) CED or a 24 h infusion via Alzet osmotic pumps.
Based on these observations, therapy studies were carried out using H2TCP and H2TBP as
boron delivery agents. The longest MST (43.8±10.0 d) was obtained using H2TBP,
compared to 35.0±3.7 d for H2TCP, both delivered by Alzet pumps, and 39.8±1.6 d for i.v.
BPA. Our results are in agreement with those recently reported by Jori et al. [45] who
observed that the tumor boron concentrations following i.t. administration of H2TCP to
C57B1/6 mice bearing s.c. implants of the B16 melanoma were 10× greater than those
observed following i.v. injection (60 versus 6 µg/g). However, following BNCT the tumor
growth delay was practically identical for both groups and these were significantly less than
those observed following i.p. administration of 200 mg/kg of BPA. Although the tumor
boron concentrations for the latter animals was not determined, published data would
suggest that it could have been in the range of 10–20 µg/g [46–48]. Similarly, Shibata et al.
[49] have reported a very modest increase in the MST of 9L gliosarcoma bearing rats that
received a BSH-porphyrin compound designated STA-BX900 (16.2 versus 14.8 d and 12.8
d for irradiated and untreated control animals, respectively). Therefore, our data are the first
to show that carboranylporphyrins can be effective delivery agent for NCT of an
experimental brain tumor.
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However, since in our study the tumor boron concentrations were so much higher following
either CED or infusion by Alzet pumps than those obtained with other boron compounds, it
was puzzling why the survival data were similar to those obtained with BPA, which had a
much lower tumor boron concentration. Histopathologic examination of brains from tumor
bearing, BNCT treated rats revealed that in most animals there were large numbers of
porphyrin containing macrophages (Fig. 5A and B) indicating that tumor cell uptake was
much lower than would have been predicted, based on the tumor boron values, as
determined by DCP-AES. This may provide a partial explanation as to why the survival data
were similar to those obtained with BPA, despite the seemingly high “tumor” boron
concentrations. One possible explanation for the high uptake of the carboranylporphyrins by
macrophages and the relatively low uptake by tumor cells could be related to their
propensity to form aggregates when high concentrations are solubilized in water. This
problem could be obviated by initially dissolving them in dimethylsulfoxide (DMSO) and
then diluting it down to 1% DMSO. Theoretically, bystander killing might occur if the 10B
containing macrophages were adjacent to tumor cells. However, the potential lethality of the
J Neurooncol. Author manuscript; available in PMC 2011 June 1.
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alpha particles produced as a result of the 10B(n,α)7Li capture reaction would be much less
than if they were produced within the tumor cells. Although CED has been effective in
improving the distribution of a variety of agents in rats with brain tumors, its effectiveness
in human has been much more problematic [30,31]. However, direct i.c. delivery of
therapeutic agents, which bypass the BBB, results in much higher concentrations in the brain
tumor and concomitantly lower concentrations in extracranial sites thereby reducing
systemic toxicity. The major problem associated with any therapeutic study carried out using
rodent brain tumor models is their relevancy to the treatment of patients with brain tumors.
The rat brain weighs approximately 1.2 gms and a human brain weighs 1,200 gms, a
thousand-fold difference. However, one thing that is reasonably certain, is that if it doesn’t
work in rats, it probably will not work in humans.
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Ozawa et al. [25,26], as well as we [32–34], have observed that CED and Alzet pump
infusion resulted in significantly higher tumor and lower normal brain boron concentrations
than those obtained following systemic administration. They were the first to report that
CED significantly increased the tumor uptake of two boronated porphyrins, designated
TABP-1 and BOPP, although no therapy results were reported [29,30]. Although CED of
the carboranylporphyrins has solved the problem of high extracranial tissue uptake by the
liver and spleen, the seemingly high tumor boron values do not seem to accurately reflect
the true intracellular uptake of the compounds, as shown for the first time by us in the
present study. Direct i.c. administration appears to be the preferred route of administration
for the presently available carboranylporphyrins. However, their enhanced intracellular
localization and microdistribution depend on the physico-chemical properties of the
carboranylporphyrins, and one of our goals is to synthesize compounds that will have
enhanced tumor cell uptake. In addition, it would be highly advantageous to have tumor
selective compounds that readily cross the blood-brain barrier and that could be
administered systemically and obtain high tumor and low normal brain and extracranial
tissue and blood concentrations. It is noteworthy that in vitro studies on the cellular uptake
of H2TCP studies with the murine B16 melanoma [19,45] cells and H2TBP with human T98
glioblastoma cells [23] demonstrated intracellular fluorescence of cells that had been
incubated with these compounds. Despite their tetra-anionic nature, they were able to
penetrate plasma membranes to a certain extent, and may not have formed aggregates, which
resulted in intense fluorescence.
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In the future, we plan to carry out studies using secondary ion mass spectrometry (SIMS)
[50]to obtain quantitative data on the boron concentrations of individual tumor cells in tissue
sections. This method has been used by us to determine the cellular and subcellular
localization of BPA [51], BSH [52] and carboranyl nucleosides [53]. Our data provide a
cautionary note that high “tumor” boron concentrations do not necessarily mean that the
boron delivery agent is localized within tumor cells. The challenge is to synthesize and
evaluate non-toxic, carboranylporphyrins that attain high in vivo tumor cell uptake following
either systemic injection or direct i.c. administration. Based on the studies of Ozawa et al.,
Jori, et al. and ourselves, it can be concluded that these compounds are a promising class of
boron delivery agents that warrant further investigation.
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Figure 1.

Chemical structures of the carboranylporphyrins used in this study: A. di[3,5-(nidocarboranylmethyl)phenyl]porphyrin (H2DCP), and its zinc(II) complex (ZnDCP), B. tetra(4nido-carboranylphenyl)porphyrin (H2TCP), and C. tetra(4-nido-carboranylphenyl)tetrabenzo-porphyrin, H2TBP (C).
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Figure 2.

Kaplan-Meier survival curves for F98 glioma bearing rats following Alzet pump delivery of
H2TCP or H2TBP followed by BNCT. Survival times in days after implantation have been
plotted for untreated animals (●), radiation controls (○), H2TCP (▲) or H2TBP (□).

NIH-PA Author Manuscript
J Neurooncol. Author manuscript; available in PMC 2011 June 1.

Kawabata et al.

Page 15

NIH-PA Author Manuscript

Figure 3.

Kaplan –Meier survival curves for F98 glioma bearing following CED of H2TBP followed
by BNCT. Survival times in days after implantation have been plotted for untreated animals
(●), irradiation controls (○), H2TBP (■), i.v. BPA (◇) and H2TBP plus BPA (◆).
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Figure 4.
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Kaplan-Meier survival curves for F98 glioma bearing rats following either CED or Alzet
pump delivery of H2TBP followed by BNCT. Survival times in days after implantation have
been plotted for untreated animals (●), radiation controls (○), CED delivery of H2TBP (■),
Alzet pump delivery of H2TBP (□).
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Figure 5.
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Low power photomicrograph from the brain of a BNCT treated, F98 glioma bearing rat
following administration of H2TBP by CED. There are large numbers of porphyrin laden
macrophages (arrows). B. High power photomicrograph showing porphyrin laden
macrophages. These photos were taken at the time of death of the animal at which time they
had progressively growing brain tumors.
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T:Br indicates the tumor to normal brain ratio and T:Bl indicates the tumor to blood ratio.

Boron concentrations were determined by DCP-AES. The mean boron values (µg/g wt of tissue) ± the standard deviation are shown for groups of 4 animals.

b

ZnDCP or ZnTCP was administered by 3 i.p. injections, administered over 8 hours to C57BL/6 mice bearing s.c. implants of the GL261 murine glioma. Animals were euthanized at 24 and 48 hrs following
the third injection and tissues and blood samples were removed for boron determinations. BPA was administered i.p. at a dose of 25 mg b/kg b.w. and mice were euthanized 2.5 h later.
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(0, 24, 48 hrs after termination) and tissues and blood samples were removed for boron determinations by DCP-AES. The values indicated are means ± SD for groups of 4–5 rats.

H2TCP (0.2 – 1.0 mg) was administered by means of Alzet osmotic pumps (#2001D) over 24 hours to Fischer rats bearing i.c. implants of the F98 glioma. Animals were euthanized at different time point
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Physical dose estimates include contributions from gamma photons, 14N (n,p), 14C and 10B (n,α) 7Li reactions.

Boron concentrations were determined in samples of tumor, brain, blood, liver, spleen, kidneys, lung and heart, by means of direct current plasma-atomic emission spectroscopy. Except as indicated above,
boron concentrations were at the undetectable level (<0.5 µg/g) in all other tissues. The values indicated are means ± standard deviation for groups of 4–5 rats.

b

euthanized 24 h after administration and tissues and blood samples were taken for boron determinations.

H2DCP, H2TCD and H2TBP at doses of 0.5 mg were administered to Fischer rats bearing i.c. implants of the F98 glioma by Alzet osmotic pumps or at a dose of 0.2 mg by CED. The animals were

a

102.9 ± 26.3

Tumor

Boron concentrations (µg/g)b

H2TCP/pump

Agent/Routea

Boron concentrations and physical radiation doses delivered in F98 glioma bearing rats 24 hrs following administration of carboranylporphyrins by
osmotic pumps or CED*
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21 – 29

24 – 31

33–48

33 – 61

30 – 39

32 – 59

30 – 41

Range

23.4±2.5

27.4±2.7

39.8±1.6

42.8±9.0

33.8±3.1

43.8±10.0

35.0±3.7

Mean ± SD

Survival Time

22.5

27

39.5

41

33.5

40.5

36

Median

-

17.3

59

70.0

44.4

87.2

49.6

Mean

-

20.0

58

75.5

48.9

80.0

60.0

Median

%ILSb

c
Percent increased life span (%ILS) was defined relative to the mean and median survival times of untreated controls.

N is the number of animals per group.

b

A total of either 0.2 mg of the compound was administered by CED for 30 min or 0.5 mg by Alzet osmotic pumps for 24 hrs. BNCT was initiated 24 hrs after termination of either CED for Alzet osmotic
pump infusion or 2.5 hrs after i.v. administration of BPA.

a

9

Irradiated
controls

10

10

BPA/i.v.

Untreated
Controls

9

H2TBP/CED+
i.v. BPA

10

H2TBP/pump

10

18

H2TCP/pump

H2TBP/CED

Na

Group

Agent/Route

Survival times of F98 glioma bearing rats following i.c. delivery of H2TCP and H2TBP by CED or osmotic pumps
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